Saturday, September 23, 2023
Saturday, September 23, 2023

LiverMultiScan Has Achieved Nationwide Payer Coverage for Diagnosis and Management of NAFLD and Other Established Chronic Liver Diseases

LiverMultiScan: AIM Specialty Health deems LiverMultiScan medically necessary for evaluating diffuse liver diseases, covering over 77 million US lives. This new AIM Advanced Imaging guideline includes the stand-alone CPT Code 0648T used when billing for the LiverMultiScan procedure.

These advances in coverage and reimbursement for LiverMultiScan procedures have the potential to help change the paradigm of liver disease care by providing broader access to patients eligible in California,” Mazen Noureddin, MD, MHSc, Cedars-Sinai Medical Center, Los Angeles, California.

LiverMultiScan is a non-invasive MRI technology that delivers a clear picture of liver health in one single scan through three key metrics – fibro-inflammation, fat, and iron – and may be an alternative to liver biopsy.1 Studies have demonstrated that LiverMultiScan is a non-invasive, clinically accurate diagnostic for identifying patients with disease activity at the point where the disease is still reversable.2 With broad coverage and reimbursement options available, more than ever before, clinicians and patients can conquer liver disease through rapid and reliable imaging with LiverMultiScan.

The new guidance directs Radiology Benefit Management decisions within the following health plans: Anthem (California, New York, Colorado, Connecticut, Georgia, Indiana, Kentucky, Missouri, Ohio, Wisconsin, Maine, New Hampshire, Nevada, Virginia), BlueCross BlueShield Alabama, BlueCross BlueShield Arkansas, BlueCross BlueShield Louisiana, BlueCross BlueShield Massachusetts, BlueCross BlueShield North Carolina, LifeWise Health Plans, Premera, and Pacificsource.

In addition, the following Medicare Administrative Contractors (MACs) have updated Hospital Outpatient fee schedules to include reimbursement of LiverMultiScan when ordered and billed as a stand-alone procedure under CPT Code 0648T: Novitas Solutions, National Government Services, Palmetto GBA, and First Coast Service Options.

Additionally, the Perspectum Coverage Support (PCS) Program assists and increases patient access to the LiverMultiScan through submission for prior authorization and patient-based appeals.

Access the New AIM Advanced Imaging guideline.


1Andrea Dennis et al., “Correlations Between MRI Biomarkers PDFF and CT1 With Histopathological Features of Non-Alcoholic Steatohepatitis,” Frontiers in Endocrinology 11 (2021): 1053,

2Anneli Andersson et al., “Clinical Utility of MRI Biomarkers for Identifying NASH Patients’ High Risk of Progression: A Multi-Center Pooled Data and Meta-Analysis,” Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, October 6, 2021, S1542-3565(21)01056-9,

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy